AAO: Considerations when using anti-VEGF for treating AMD

Stem cells may replace some lost retinal neurons

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution), commercialised as EvoTears in Europe, is the first prescription eye drop that targets tear evaporation.

OWL's ESCRS 2023 event on Sunday, September 10, at 7 pm, promises an evening of visionary leadership and collaboration in ophthalmic innovation.

Commonly used immunosuppressants used in the short term to control an ocular inflammatory disease were not associated with increased risk of developing cancer later.